<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04775654</url>
  </required_header>
  <id_info>
    <org_study_id>21-02-7800</org_study_id>
    <nct_id>NCT04775654</nct_id>
  </id_info>
  <brief_title>The Effects of Blackcurrant Supplementation on Eye Health</brief_title>
  <official_title>The Effects of Blackcurrant Supplementation on Eye Health: a Randomized, Double Blind, Placebo Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Franklin School of Integrative Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Artemis International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Franklin School of Integrative Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the potential for supplementation with black currant&#xD;
      to support eye health among otherwise healthy adult women who spend 6+ hours per day using&#xD;
      digital screens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women who are informed about the study and provide informed consent will be randomized to one&#xD;
      of two groups: supplement and placebo. Group assignment will be a 1:1 ratio to supplement&#xD;
      (455mg of blackcurrant standardized to 50mg anthocyanins in 2 capsules/day) or placebo (2&#xD;
      capsules/day). Outcomes will be assessed at baseline and again on day 70.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Actual">October 29, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Participants and the individuals providing informed consent are masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in ocular discomfort on day 70.</measure>
    <time_frame>Baseline and day 70</time_frame>
    <description>The Ocular Discomfort scale is a validated self reported instrument assessing ocular discomfort symptoms. The scale contains 6 domains with a combination of likert scale (ranging from 1-7) and dichotomous (yes/no) questions. Higher scores indicate greater visual fatigue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in visual fatigue on day 70.</measure>
    <time_frame>Baseline and day 70</time_frame>
    <description>The Visual Fatigue scale is a validated self reported instrument assessing visual fatigue symptoms. It is a 6-question scale which asks about immediate symptoms (such as dry eyes). Participants rank their symptoms on a likert scale scored from 1-7, with higher scores indicating more severe symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in computer vision symptoms on day 70.</measure>
    <time_frame>Baseline and day 70</time_frame>
    <description>The Computer Vision Symptom scale is a validated self reported instrument assessing computer vision symptoms. The scale measures 17 symptom domains, with scores ranging from 1-4 to 1-7. On each domain, higher scores indicate greater severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in symptoms of computer vision syndrome on day 70.</measure>
    <time_frame>Baseline and day 70</time_frame>
    <description>The Computer Vision Syndrome Questionnaire is a validated self reported instrument assessing computer vision symptoms. The scale measures the presence or absence of 16 symptoms producing scores from 0-16. Higher scores indicate more symptoms.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Eye Strain</condition>
  <condition>Eye Fatigue</condition>
  <arm_group>
    <arm_group_label>Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants consume 455mg of blackcurrant extract standardized to contain 50mg anthocyanins in a 2-capsule dose for 70 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants consume 2 capsules of microcrystalline cellulose for 70 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Blackcurrant</intervention_name>
    <description>Two capsules containing 455mg of CurrantCraft 11% black currant extract.</description>
    <arm_group_label>Supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two capsules containing an inert material.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Age 30-60&#xD;
&#xD;
          -  Lives in the United States&#xD;
&#xD;
          -  Employed full time in an online work environment OR enrolled full time in an online&#xD;
             learning environment (average of 6+ hours per day)&#xD;
&#xD;
          -  Ability to understand study instructions&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
          -  Residence within 100 miles of the study center&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Low blood pressure&#xD;
&#xD;
          -  Uncontrolled hypertension (i.e. systolic/diastolic blood pressure &gt; 140/90)&#xD;
&#xD;
          -  Uncontrolled diabetes (i.e. fasting blood glucose &gt;180mg/dl)&#xD;
&#xD;
          -  Any blood clotting disorder&#xD;
&#xD;
          -  Ocular disease&#xD;
&#xD;
          -  Best corrected visual acuity &lt;20/30&#xD;
&#xD;
          -  Cataracts&#xD;
&#xD;
          -  Renal disease&#xD;
&#xD;
          -  Active hepatitis or cirrhosis&#xD;
&#xD;
          -  Acute or chronic infectious disease&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Currently trying to conceive&#xD;
&#xD;
          -  Surgical or other invasive procedure planned within the intervention period&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessie R Hawkins, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Franklin Health Research &amp; Education Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessie R Hawkins, PhD</last_name>
    <phone>61527613116</phone>
    <email>info@franklinhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christy Hires, MPH</last_name>
    <phone>6152613116</phone>
    <email>info@franklinhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Franklin Health Research Center</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessie Hawkins, PhD</last_name>
      <phone>615-642-1919</phone>
      <email>j.hawkins@franklinhealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>black currant</keyword>
  <keyword>blackcurrant</keyword>
  <keyword>Ribes nigrum</keyword>
  <keyword>digital eye fatigue</keyword>
  <keyword>eye health</keyword>
  <keyword>computer vision syndrome</keyword>
  <keyword>dietary supplement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthenopia</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

